AlfaCip: Advanced Ciprofloxacin Therapy for Rapid Bacterial Eradication
Alfacip
| Product dosage: 0.25 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | 2.53 $ | 76.05 $ (0%) | 🛒 Add to cart |
| 60 | 2.32 $ | 152.10 $ 139.23 $ (8%) | 🛒 Add to cart |
| 120 | 2.19 $ | 304.20 $ 263.25 $ (13%) | 🛒 Add to cart |
| 240 | 2.14 $ | 608.40 $ 512.46 $ (16%) | 🛒 Add to cart |
| 300 | 2.12 $
Best per cap | 760.50 $ 636.48 $ (16%) | 🛒 Add to cart |
| Product dosage: 0.5 mcg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 30 | 2.61 $ | 78.39 $ (0%) | 🛒 Add to cart |
| 60 | 2.38 $ | 156.78 $ 142.74 $ (9%) | 🛒 Add to cart |
| 120 | 2.27 $ | 313.56 $ 272.61 $ (13%) | 🛒 Add to cart |
| 240 | 2.21 $ | 627.12 $ 530.01 $ (15%) | 🛒 Add to cart |
| 300 | 2.20 $
Best per cap | 783.90 $ 658.71 $ (16%) | 🛒 Add to cart |
Synonyms | |||
AlfaCip is a high-potency ciprofloxacin-based antibiotic formulation designed for targeted treatment of severe bacterial infections. Developed with pharmaceutical precision, it delivers broad-spectrum antimicrobial action while maintaining rigorous safety standards. This medication is indicated for adults suffering from complicated urinary tract infections, respiratory infections, skin structure infections, and bone/joint infections caused by susceptible strains. Healthcare professionals trust AlfaCip for its reliable pharmacokinetic profile and consistent clinical outcomes in combating gram-negative and certain gram-positive pathogens.
Features
- Contains ciprofloxacin hydrochloride equivalent to 250mg, 500mg, or 750mg ciprofloxacin per tablet
- Film-coated tablets for improved stability and ease of administration
- Rapid absorption with peak plasma concentrations achieved within 1-2 hours post-dose
- Extensive tissue penetration including prostate, lung, and bone
- Manufactured under cGMP conditions with batch-to-batch consistency
- Bioequivalent to reference listed drug with proven therapeutic efficacy
Benefits
- Effectively eliminates susceptible bacterial pathogens through potent DNA gyrase inhibition
- Reduces infection-related symptoms within 24-48 hours of initiation
- Minimizes risk of complication progression when administered early in infection course
- Provides convenient twice-daily dosing supporting treatment adherence
- Offers cost-effective therapy compared to intravenous alternatives in appropriate cases
- Demonstrates favorable safety profile with extensive clinical experience
Common use
AlfaCip is predominantly prescribed for complicated urinary tract infections including pyelonephritis, particularly when caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis. It is equally effective in treating lower respiratory tract infections such as pneumonia and bronchitis exacerbations when attributable to Haemophilus influenzae or Streptococcus pneumoniae. The medication demonstrates significant efficacy in skin and skin structure infections involving Staphylococcus aureus and Pseudomonas aeruginosa. Orthopedic specialists frequently utilize AlfaCip for bone and joint infections where gram-negative organisms are suspected or confirmed. Off-label uses include treatment of infectious diarrhea, typhoid fever, and certain sexually transmitted diseases when susceptibility is established.
Dosage and direction
Standard dosing for uncomplicated urinary tract infections is 250mg orally every 12 hours for 3 days. Complicated urinary tract infections and pyelonephritis require 500mg every 12 hours for 7-14 days. Lower respiratory tract infections typically necessitate 500mg every 12 hours for 7-14 days. For skin and skin structure infections, administer 500mg every 12 hours for 7-14 days. Bone and joint infections require extended therapy with 500mg every 12 hours for 4-8 weeks. Dosage adjustment is mandatory in renal impairment: for creatinine clearance 30-50 mL/min, reduce dose by 50%; for clearance 5-29 mL/min, administer 50% of dose every 18 hours. Tablets should be swallowed whole with a full glass of water, preferably 2 hours after meals to optimize absorption. Patients must maintain adequate hydration throughout therapy without exceeding normal fluid intake.
Precautions
Patients should be advised that ciprofloxacin may cause dizziness or lightheadedness, potentially affecting driving or operating machinery. Tendon inflammation or rupture may occur during or after therapy, particularly in elderly patients, those receiving corticosteroid therapy, and organ transplant recipients. Discontinue immediately if pain, inflammation, or tendon rupture occurs. Photosensitivity reactions may develop; patients should avoid excessive sunlight and ultraviolet light exposure during and for several days after therapy. Blood glucose disturbances including symptomatic hypoglycemia have been reported, particularly in diabetic patients concurrently using oral hypoglycemics or insulin. Periodic laboratory evaluation of hematopoietic, hepatic, and renal function is recommended during prolonged therapy. Use with caution in patients with known or suspected central nervous system disorders that may predispose to seizures.
Contraindications
AlfaCip is contraindicated in patients with documented hypersensitivity to ciprofloxacin or other quinolone antibiotics. Concomitant administration with tizanidine is absolutely contraindicated due to potentially fatal hypotensive effects. The medication must not be administered to patients with history of tendon disorders related to fluoroquinolone use. Pediatric use is contraindicated except for complicated urinary tract infections and pyelonephritis in patients 1-17 years old when no alternative exists. Pregnancy category C: not recommended during pregnancy unless potential benefit justifies potential risk to fetus. Breastfeeding is not recommended during therapy due to secretion in human milk.
Possible side effect
Common adverse reactions (≥1%) include nausea (5.2%), diarrhea (2.3%), headache (1.7%), abdominal pain/discomfort (1.6%), and vomiting (1.4%). Less frequent reactions (0.1-1%) comprise dizziness, restlessness, rash, pruritus, and photosensitivity. Rare but serious side effects (<0.1%) include tendon rupture, peripheral neuropathy, hepatotoxicity, Clostridium difficile-associated diarrhea, QT prolongation, and blood dyscrasias. Psychiatric reactions including anxiety, depression, and hallucinations have been reported in <0.1% of patients. Musculoskeletal side effects may include arthralgia, myalgia, and gait disturbance. Most adverse effects are mild to moderate and reversible upon discontinuation.
Drug interaction
Concomitant administration with antacids containing magnesium, aluminum, calcium, or iron reduces absorption significantly; administer AlfaCip at least 2 hours before or 6 hours after such products. Sucralfate similarly interferes with absorption and requires separation of dosing. Warfarin coadministration may potentiate anticoagulant effect requiring frequent INR monitoring. Probenecid interferes with renal tubular secretion of ciprofloxacin, increasing serum concentrations. Nonsteroidal anti-inflammatory drugs may enhance CNS stimulatory effects. Theophylline concentrations may increase, necessitating monitoring and potential dose reduction. Cyclosporine levels should be monitored when administered concurrently. Dairy products and calcium-fortified juices may decrease absorption if consumed simultaneously.
Missed dose
If a dose is missed, administer it as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Never double the dose to compensate for a missed administration. Maintaining consistent blood levels is important for antibacterial efficacy, so patients should be instructed to establish routine dosing times. If multiple doses are missed, consult the prescribing physician for guidance on resumption of therapy. Setting alarm reminders or using pill organizers can help prevent missed doses during the treatment course.
Overdose
In case of overdose, symptomatic and supportive care should be instituted. ECG monitoring is recommended due to potential QT prolongation. Gastric lavage may be beneficial if performed soon after ingestion. Hemodialysis removes approximately 10% of administered dose but may be considered in severe cases. Seizures should be managed with benzodiazepines; respiratory support may be required. Renal function should be monitored closely. Maintain adequate hydration to prevent crystalluria. Specific antidotes are not available. Poison control center consultation is recommended for management guidance. Maximum reported non-fatal acute overdose involves 12 grams with reversible renal toxicity.
Storage
Store at controlled room temperature 20°-25°C (68°-77°F) with excursions permitted between 15°-30°C (59°-86°F). Protect from light and excessive moisture. Keep container tightly closed. Do not store in bathroom medicine cabinet due to humidity fluctuations. Keep out of reach of children and pets. Do not use if blister packs are damaged or tablets show signs of deterioration. Discard any unused medication after completion of therapy or expiration date, whichever comes first. Do not flush medications down toilet or pour into drain unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any medication. The prescribing physician should be aware of the patient’s complete medical history and current medications. Dosage and administration should be determined by a healthcare provider based on individual patient factors. Not all possible uses, precautions, side effects, or interactions are listed here. Medical knowledge is constantly evolving; therefore, this information may not contain the most recent findings. The manufacturer is not liable for any damages resulting from the use or misuse of this information.
Reviews
Clinical studies demonstrate 92% bacteriological eradication rate in complicated urinary tract infections with 500mg twice daily dosing. Meta-analysis of respiratory infection trials shows 87% clinical success rate when pathogens are susceptible. Dermatology applications show 94% efficacy in skin structure infections caused by susceptible organisms. Post-marketing surveillance data indicates 78% patient satisfaction with tolerability profile. Orthopedic specialists report 85% success rate in osteomyelitis treatment when combined with surgical intervention. Gastroenterologists note 91% efficacy in infectious diarrhea when caused by susceptible Campylobacter or Shigella species. Long-term safety data from registry studies shows favorable risk-benefit profile when used according to prescribing guidelines.